Clinical Trials Logo

Advanced Solid Tumours clinical trials

View clinical trials related to Advanced Solid Tumours.

Filter by:

NCT ID: NCT02430311 Completed - Clinical trials for Advanced Solid Tumours

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Start date: June 10, 2015
Phase: Phase 1
Study type: Interventional

This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours. Part A will assess the single and multiple dose pharmacokinetics of olaparib monotherapy and multiple dose pharmacokinetics of olaparib in combination with paclitaxel. Part B will assess the safety of multiple doses of olaparib in Cohort 1 and of olaparib when co-administered with paclitaxel in Cohort 2

NCT ID: NCT02341456 Completed - Clinical trials for Advanced Solid Tumours

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Start date: January 16, 2015
Phase: Phase 1
Study type: Interventional

This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.

NCT ID: NCT02042781 Completed - Clinical trials for Advanced Solid Tumours

Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours

Start date: January 2014
Phase: Phase 1
Study type: Interventional

This Phase Ia study aims to establish the maximum tolerated dose of once-weekly IV infused PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition, the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.

NCT ID: NCT01585701 Completed - Clinical trials for Advanced Solid Tumours

Phase I Study of AT13148, a Novel AGC Kinase Inhibitor

Start date: May 2012
Phase: Phase 1
Study type: Interventional

The purpose of this first clinical study of the noval multiple AGC kinase inhibitor, AT13148, is to identify the recommended dose for future studies in cancer patients by exploring the safety and maximum tolerated dose and biological effects in patients with advanced solid tumours.

NCT ID: NCT01163903 Completed - Clinical trials for Advanced Solid Tumours

Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours

Start date: July 2010
Phase: Phase 1
Study type: Interventional

This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment options. A minimum of 3 patients will be enrolled per dose level and intra-patient dose escalation is not permitted. Once the RP2D has been identified, six additional patients with metastatic solid tumours will be treated at the RP2D to confirm its tolerability.

NCT ID: NCT01058538 Completed - Clinical trials for Advanced Solid Tumours

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Start date: November 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed against the ED-B domain of fibronectin, one of the most important markers for neoangiogenesis, and the human cytokine interleukin-2 (IL2).